Intrinsic value of DexCom, Inc. - DXCM

Previous Close

$160.49

  Intrinsic Value

$7.25

stock screener

  Rating & Target

str. sell

-95%

Previous close

$160.49

 
Intrinsic value

$7.25

 
Up/down potential

-95%

 
Rating

str. sell

We calculate the intrinsic value of DXCM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 14.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  52.90
  48.11
  43.80
  39.92
  36.43
  33.28
  30.46
  27.91
  25.62
  23.56
  21.70
  20.03
  18.53
  17.18
  15.96
  14.86
  13.88
  12.99
  12.19
  11.47
  10.82
  10.24
  9.72
  9.25
  8.82
  8.44
  8.09
  7.79
  7.51
  7.26
Revenue, $m
  1,578
  2,337
  3,361
  4,702
  6,415
  8,550
  11,154
  14,268
  17,923
  22,145
  26,951
  32,350
  38,344
  44,930
  52,099
  59,842
  68,146
  76,997
  86,383
  96,291
  106,714
  117,642
  129,074
  141,007
  153,445
  166,394
  179,863
  193,866
  208,419
  223,543
Variable operating expenses, $m
  1,661
  2,452
  3,518
  4,915
  6,698
  8,922
  11,633
  14,875
  18,681
  23,077
  28,063
  33,685
  39,926
  46,784
  54,249
  62,312
  70,958
  80,175
  89,948
  100,265
  111,117
  122,497
  134,400
  146,826
  159,777
  173,260
  187,286
  201,867
  217,020
  232,768
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  1,661
  2,452
  3,518
  4,915
  6,698
  8,922
  11,633
  14,875
  18,681
  23,077
  28,063
  33,685
  39,926
  46,784
  54,249
  62,312
  70,958
  80,175
  89,948
  100,265
  111,117
  122,497
  134,400
  146,826
  159,777
  173,260
  187,286
  201,867
  217,020
  232,768
Operating income, $m
  -83
  -115
  -157
  -212
  -283
  -371
  -479
  -607
  -758
  -932
  -1,112
  -1,335
  -1,582
  -1,854
  -2,150
  -2,470
  -2,812
  -3,177
  -3,565
  -3,974
  -4,404
  -4,855
  -5,327
  -5,819
  -6,332
  -6,867
  -7,422
  -8,000
  -8,601
  -9,225
EBITDA, $m
  -23
  -33
  -48
  -67
  -92
  -123
  -160
  -204
  -257
  -317
  -386
  -464
  -550
  -644
  -747
  -858
  -977
  -1,104
  -1,238
  -1,380
  -1,529
  -1,686
  -1,850
  -2,021
  -2,199
  -2,385
  -2,578
  -2,778
  -2,987
  -3,204
Interest expense (income), $m
  0
  55
  43
  70
  106
  154
  214
  290
  382
  493
  622
  772
  942
  1,134
  1,346
  1,580
  1,834
  2,108
  2,403
  2,716
  3,049
  3,400
  3,770
  4,157
  4,562
  4,985
  5,426
  5,885
  6,363
  6,859
  7,375
Earnings before tax, $m
  -138
  -158
  -227
  -318
  -437
  -585
  -769
  -989
  -1,251
  -1,554
  -1,884
  -2,277
  -2,716
  -3,200
  -3,730
  -4,303
  -4,920
  -5,580
  -6,281
  -7,023
  -7,804
  -8,625
  -9,484
  -10,381
  -11,318
  -12,293
  -13,308
  -14,363
  -15,460
  -16,600
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -138
  -158
  -227
  -318
  -437
  -585
  -769
  -989
  -1,251
  -1,554
  -1,884
  -2,277
  -2,716
  -3,200
  -3,730
  -4,303
  -4,920
  -5,580
  -6,281
  -7,023
  -7,804
  -8,625
  -9,484
  -10,381
  -11,318
  -12,293
  -13,308
  -14,363
  -15,460
  -16,600

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,151
  1,705
  2,451
  3,430
  4,679
  6,237
  8,136
  10,407
  13,073
  16,153
  19,658
  23,596
  27,968
  32,771
  38,001
  43,649
  49,705
  56,161
  63,007
  70,234
  77,836
  85,808
  94,146
  102,850
  111,922
  121,367
  131,191
  141,405
  152,020
  163,051
Adjusted assets (=assets-cash), $m
  1,151
  1,705
  2,451
  3,430
  4,679
  6,237
  8,136
  10,407
  13,073
  16,153
  19,658
  23,596
  27,968
  32,771
  38,001
  43,649
  49,705
  56,161
  63,007
  70,234
  77,836
  85,808
  94,146
  102,850
  111,922
  121,367
  131,191
  141,405
  152,020
  163,051
Revenue / Adjusted assets
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
  1.371
Average production assets, $m
  264
  390
  561
  785
  1,071
  1,428
  1,863
  2,383
  2,993
  3,698
  4,501
  5,402
  6,403
  7,503
  8,701
  9,994
  11,380
  12,859
  14,426
  16,081
  17,821
  19,646
  21,555
  23,548
  25,625
  27,788
  30,037
  32,376
  34,806
  37,332
Working capital, $m
  140
  208
  299
  418
  571
  761
  993
  1,270
  1,595
  1,971
  2,399
  2,879
  3,413
  3,999
  4,637
  5,326
  6,065
  6,853
  7,688
  8,570
  9,498
  10,470
  11,488
  12,550
  13,657
  14,809
  16,008
  17,254
  18,549
  19,895
Total debt, $m
  793
  1,292
  1,964
  2,844
  3,969
  5,371
  7,080
  9,124
  11,523
  14,295
  17,450
  20,994
  24,929
  29,252
  33,958
  39,041
  44,493
  50,303
  56,464
  62,969
  69,810
  76,985
  84,489
  92,322
  100,487
  108,988
  117,830
  127,022
  136,576
  146,503
Total liabilities, $m
  1,036
  1,534
  2,206
  3,087
  4,211
  5,613
  7,322
  9,366
  11,766
  14,537
  17,692
  21,236
  25,171
  29,494
  34,201
  39,284
  44,735
  50,545
  56,706
  63,211
  70,053
  77,227
  84,731
  92,565
  100,730
  109,230
  118,072
  127,264
  136,818
  146,746
Total equity, $m
  115
  170
  245
  343
  468
  624
  814
  1,041
  1,307
  1,615
  1,966
  2,360
  2,797
  3,277
  3,800
  4,365
  4,971
  5,616
  6,301
  7,023
  7,784
  8,581
  9,415
  10,285
  11,192
  12,137
  13,119
  14,140
  15,202
  16,305
Total liabilities and equity, $m
  1,151
  1,704
  2,451
  3,430
  4,679
  6,237
  8,136
  10,407
  13,073
  16,152
  19,658
  23,596
  27,968
  32,771
  38,001
  43,649
  49,706
  56,161
  63,007
  70,234
  77,837
  85,808
  94,146
  102,850
  111,922
  121,367
  131,191
  141,404
  152,020
  163,051
Debt-to-equity ratio
  6.890
  7.580
  8.010
  8.290
  8.480
  8.610
  8.700
  8.770
  8.810
  8.850
  8.880
  8.900
  8.910
  8.930
  8.940
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.980
  8.980
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -138
  -158
  -227
  -318
  -437
  -585
  -769
  -989
  -1,251
  -1,554
  -1,884
  -2,277
  -2,716
  -3,200
  -3,730
  -4,303
  -4,920
  -5,580
  -6,281
  -7,023
  -7,804
  -8,625
  -9,484
  -10,381
  -11,318
  -12,293
  -13,308
  -14,363
  -15,460
  -16,600
Depreciation, amort., depletion, $m
  61
  81
  109
  145
  191
  249
  319
  403
  501
  615
  726
  871
  1,033
  1,210
  1,403
  1,612
  1,836
  2,074
  2,327
  2,594
  2,874
  3,169
  3,477
  3,798
  4,133
  4,482
  4,845
  5,222
  5,614
  6,021
Funds from operations, $m
  -77
  -76
  -118
  -173
  -246
  -337
  -450
  -587
  -750
  -940
  -1,158
  -1,406
  -1,683
  -1,990
  -2,326
  -2,691
  -3,085
  -3,506
  -3,954
  -4,429
  -4,930
  -5,456
  -6,007
  -6,583
  -7,185
  -7,811
  -8,463
  -9,141
  -9,846
  -10,579
Change in working capital, $m
  49
  68
  91
  119
  152
  190
  232
  277
  325
  376
  428
  480
  533
  586
  638
  689
  739
  788
  835
  882
  928
  973
  1,017
  1,062
  1,107
  1,152
  1,199
  1,246
  1,295
  1,346
Cash from operations, $m
  -126
  -144
  -209
  -293
  -398
  -527
  -682
  -864
  -1,075
  -1,315
  -1,586
  -1,886
  -2,217
  -2,576
  -2,964
  -3,381
  -3,824
  -4,294
  -4,790
  -5,311
  -5,857
  -6,428
  -7,024
  -7,645
  -8,292
  -8,964
  -9,662
  -10,388
  -11,141
  -11,925
Maintenance CAPEX, $m
  -28
  -43
  -63
  -91
  -127
  -173
  -230
  -300
  -384
  -483
  -596
  -726
  -871
  -1,033
  -1,210
  -1,403
  -1,612
  -1,836
  -2,074
  -2,327
  -2,594
  -2,874
  -3,169
  -3,477
  -3,798
  -4,133
  -4,482
  -4,845
  -5,222
  -5,614
New CAPEX, $m
  -91
  -127
  -171
  -224
  -286
  -357
  -435
  -520
  -610
  -705
  -803
  -902
  -1,001
  -1,100
  -1,197
  -1,293
  -1,387
  -1,478
  -1,567
  -1,655
  -1,740
  -1,825
  -1,909
  -1,993
  -2,077
  -2,162
  -2,249
  -2,339
  -2,430
  -2,526
Cash from investing activities, $m
  -119
  -170
  -234
  -315
  -413
  -530
  -665
  -820
  -994
  -1,188
  -1,399
  -1,628
  -1,872
  -2,133
  -2,407
  -2,696
  -2,999
  -3,314
  -3,641
  -3,982
  -4,334
  -4,699
  -5,078
  -5,470
  -5,875
  -6,295
  -6,731
  -7,184
  -7,652
  -8,140
Free cash flow, $m
  -245
  -313
  -443
  -607
  -811
  -1,056
  -1,347
  -1,684
  -2,070
  -2,503
  -2,985
  -3,514
  -4,089
  -4,709
  -5,372
  -6,077
  -6,823
  -7,608
  -8,431
  -9,292
  -10,191
  -11,128
  -12,102
  -13,115
  -14,167
  -15,259
  -16,393
  -17,571
  -18,794
  -20,064
Issuance/(repayment) of debt, $m
  -217
  498
  672
  881
  1,124
  1,402
  1,709
  2,044
  2,400
  2,772
  3,155
  3,544
  3,935
  4,323
  4,707
  5,083
  5,451
  5,810
  6,161
  6,505
  6,842
  7,174
  7,504
  7,834
  8,165
  8,500
  8,842
  9,192
  9,554
  9,928
Issuance/(repurchase) of shares, $m
  753
  213
  301
  416
  562
  741
  959
  1,216
  1,517
  1,862
  2,235
  2,671
  3,153
  3,681
  4,253
  4,868
  5,526
  6,226
  6,966
  7,745
  8,564
  9,422
  10,318
  11,252
  12,225
  13,237
  14,290
  15,385
  16,522
  17,703
Cash from financing (excl. dividends), $m  
  536
  711
  973
  1,297
  1,686
  2,143
  2,668
  3,260
  3,917
  4,634
  5,390
  6,215
  7,088
  8,004
  8,960
  9,951
  10,977
  12,036
  13,127
  14,250
  15,406
  16,596
  17,822
  19,086
  20,390
  21,737
  23,132
  24,577
  26,076
  27,631
Total cash flow (excl. dividends), $m
  291
  398
  530
  690
  875
  1,087
  1,321
  1,576
  1,847
  2,131
  2,405
  2,701
  2,999
  3,295
  3,587
  3,874
  4,155
  4,428
  4,696
  4,958
  5,215
  5,468
  5,719
  5,971
  6,223
  6,479
  6,739
  7,006
  7,281
  7,567
Retained Cash Flow (-), $m
  -753
  -213
  -301
  -416
  -562
  -741
  -959
  -1,216
  -1,517
  -1,862
  -2,235
  -2,671
  -3,153
  -3,681
  -4,253
  -4,868
  -5,526
  -6,226
  -6,966
  -7,745
  -8,564
  -9,422
  -10,318
  -11,252
  -12,225
  -13,237
  -14,290
  -15,385
  -16,522
  -17,703
Prev. year cash balance distribution, $m
  1,163
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  701
  185
  229
  273
  314
  345
  363
  359
  330
  268
  170
  30
  -154
  -386
  -665
  -994
  -1,372
  -1,797
  -2,270
  -2,788
  -3,350
  -3,954
  -4,598
  -5,281
  -6,002
  -6,759
  -7,551
  -8,378
  -9,240
  -10,137
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  672
  170
  199
  225
  243
  251
  245
  225
  190
  141
  81
  13
  -59
  -129
  -195
  -253
  -298
  -331
  -349
  -354
  -346
  -328
  -301
  -269
  -233
  -197
  -162
  -130
  -101
  -76
Current shareholders' claim on cash, %
  50.0
  42.2
  35.9
  30.6
  26.3
  22.7
  19.7
  17.1
  15.0
  13.1
  11.5
  10.1
  8.9
  7.9
  7.0
  6.2
  5.5
  4.9
  4.3
  3.9
  3.5
  3.1
  2.7
  2.5
  2.2
  2.0
  1.8
  1.6
  1.4
  1.3

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

FINANCIAL RATIOS  of  DexCom, Inc. (DXCM)

Valuation Ratios
P/E Ratio -205.7
Price to Sales 23.7
Price to Book 47.8
Price to Tangible Book
Price to Cash Flow 242.5
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate 42.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 69.7%
Cap. Spend. - 3 Yr. Gr. Rate 47.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -19%
Ret/ On Assets - 3 Yr. Avg. -19.2%
Return On Total Capital -26%
Ret/ On T. Cap. - 3 Yr. Avg. -25.4%
Return On Equity -26.1%
Return On Equity - 3 Yr. Avg. -26%
Asset Turnover 1.6
Profitability Ratios
Gross Margin 66%
Gross Margin - 3 Yr. Avg. 67.7%
EBITDA Margin -8.7%
EBITDA Margin - 3 Yr. Avg. -8.6%
Operating Margin -11.2%
Oper. Margin - 3 Yr. Avg. -11.3%
Pre-Tax Margin -11.3%
Pre-Tax Margin - 3 Yr. Avg. -11.4%
Net Profit Margin -11.5%
Net Profit Margin - 3 Yr. Avg. -11.5%
Effective Tax Rate -1.5%
Eff/ Tax Rate - 3 Yr. Avg. -0.5%
Payout Ratio 0%

DXCM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the DXCM stock intrinsic value calculation we used $1032 million for the last fiscal year's total revenue generated by DexCom, Inc.. The default revenue input number comes from 0001 income statement of DexCom, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our DXCM stock valuation model: a) initial revenue growth rate of 52.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for DXCM is calculated based on our internal credit rating of DexCom, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of DexCom, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of DXCM stock the variable cost ratio is equal to 105.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for DXCM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for DexCom, Inc..

Corporate tax rate of 27% is the nominal tax rate for DexCom, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the DXCM stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for DXCM are equal to 16.7%.

Life of production assets of 6.2 years is the average useful life of capital assets used in DexCom, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for DXCM is equal to 8.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $663.3 million for DexCom, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 90.000 million for DexCom, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of DexCom, Inc. at the current share price and the inputted number of shares is $14.4 billion.

RELATED COMPANIES Price Int.Val. Rating
TNDM Tandem Diabete 68.57 116.91  str.buy
JNJ Johnson & John 128.21 107.87  sell
ABT Abbott Laborat 86.04 44.34  sell
DRIO DarioHealth Co 0.403 0.03  str.sell
CAH Cardinal Healt 45.43 157.75  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.